ALLMedicine™ Heparin-induced Thrombocytopenia Center

Feb 23rd, 2021 - In heparin-induced thrombocytopenia (HIT), selected patients are treated with therapies directed at the immune response, intravenous immunoglobulin (IVIG) and therapeutic plasma exchange (TPE). To determine IVIG and TPE characteristics and outcome...

Feb 14th, 2021 - Heparin-induced thrombocytopenia (HIT) is a highly thrombogenic condition. Cancer patients are already at high risk of thrombosis. The treatment and outcomes of HIT in cancer patients are not well established. We retrospectively identified patient...

Feb 7th, 2021 - Heparin-induced thrombocytopenia (HIT) is a severe adverse reaction to heparin caused by heparin-dependent, platelet activating anti-platelet factor 4 (PF4)/heparin antibodies. Heparin is a cornerstone of treatment in critically ill COVID-19 patie...

Feb 2nd, 2021 - Antibodies specific for platelet factor 4 (PF4)/heparin complexes are central to the pathogenesis of heparin-induced thrombocytopenia. Marginal zone B cells appear to be the source of such antibodies, but whether T-cell help is required is unclear...

Jan 16th, 2021 - Heparin-induced thrombocytopenia (HIT) is characterized by anti-heparin/platelet factor 4 immune complexes, which are removed by therapeutic plasma exchange (TPE). Our main objective was to study TPE outcomes in HIT using a large administrative cl...

Nov 29th, 2018 - Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism. These evidence-based ...

Nov 26th, 2018 - Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism.

Nov 19th, 2016 - Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH.|2016|Morel-Kopp MC,Mullier F,Gkalea V,Bakchoul T,Minet V,|adverse effects,adverse effects,drug effects,instru...

Oct 9th, 2012 - Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.|2012|Watson H,Davidson S,Keeling D, ,|adverse effects,adverse effects,chemically induced,diagnosis,therapy,

Feb 14th, 2012 - Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction that can lead to devastating thromboembolic complications, including pulmonary embolism, ischemic limb necrosis necessitating limb amputation, acute myocardial in...

Feb 23rd, 2021 - In heparin-induced thrombocytopenia (HIT), selected patients are treated with therapies directed at the immune response, intravenous immunoglobulin (IVIG) and therapeutic plasma exchange (TPE). To determine IVIG and TPE characteristics and outcome...

Feb 14th, 2021 - Heparin-induced thrombocytopenia (HIT) is a highly thrombogenic condition. Cancer patients are already at high risk of thrombosis. The treatment and outcomes of HIT in cancer patients are not well established. We retrospectively identified patient...

Feb 7th, 2021 - Heparin-induced thrombocytopenia (HIT) is a severe adverse reaction to heparin caused by heparin-dependent, platelet activating anti-platelet factor 4 (PF4)/heparin antibodies. Heparin is a cornerstone of treatment in critically ill COVID-19 patie...

Feb 2nd, 2021 - Antibodies specific for platelet factor 4 (PF4)/heparin complexes are central to the pathogenesis of heparin-induced thrombocytopenia. Marginal zone B cells appear to be the source of such antibodies, but whether T-cell help is required is unclear...

Jan 31st, 2021 - Argatroban is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT). (1.1)  As an anticoagulant in adults patients with or at risk for HIT undergoing percuta...

Dec 13th, 2018 - SAN DIEGO — Three clinicians were hailed as Choosing Wisely Champions here at the American Society of Hematology (ASH) 2018 annual meeting for their efforts to reduce overuse of treatments and tests. One clinician describes how his team managed to...

Dec 13th, 2018 - SAN DIEGO — Three clinicians were hailed as Choosing Wisely Champions here at the American Society of Hematology (ASH) 2018 annual meeting for their efforts to reduce overuse of treatments and tests. One clinician describes how his team managed to...

Apr 8th, 2018 - At the prespecified screening cut-off of 2 or more points, the HEP Score was 97. 7% sensitive and 21.

Apr 4th, 2018 - Platelet-rich plasma HIT Confirm, a test used to diagnose heparin-induced thrombocytopenia (HIT), has received the CE mark. This means the test meets regulatory requirements and health, safety, and environmental protection standards for products s.

Jan 20th, 2018 - Action Points The first-ever clinical practice guidelines aimed at standardizing the use of blood thinners during heart surgery emphasize optimal heparin dosing during bypass, identification of contraindications to heparin use and heparin alternat...